Actinobac Biomed, Inc. signs technology licensing agreement with Elanco

NEW BRUNSWICK, N.J., June 22, 2015 /PRNewswire-USNewswire/ -- Actinobac Biomed, Inc., announced today that it has signed an agreement with Elanco Animal Health, a division of Eli Lilly and Company, to license Actinobac's non-human rights for the therapeutic uses of its primary drug candidate, Leukothera®.

The agreement allows Elanco to develop products for the treatment of food animal and companion animal diseases.

"We are extremely encouraged by Elanco's interest in our company's technology and its animal health potential. It is further recognition of our innovative approach to treat diseases that affect white blood cells which may address unmet needs in the field of animal health," said Dr. Benjamin Belinka, president and CEO of Actinobac.

Financial details were not disclosed.

About Actinobac Biomed, Inc.
Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers (leukemia & lymphoma), autoimmune/inflammatory diseases (psoriasis), and HIV infection. Our drug candidates are based upon Leukothera®, a protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Leukothera® functions by efficiently targeting and depleting the activated immune cells involved in the mechanism of these common medical conditions without affecting other tissues or organs of the body.

Further information is available on the Company's website,, or by contacting Benjamin Belinka at [email protected]


SOURCE Actinobac Biomed, Inc.



Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…